Inactive Instrument

News Asarina Pharma AB (publ) Nasdaq Stockholm

Equities

SE0011641794

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023	02-27	AQ
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB	11-30	AQ
Asarina Pharma updates on partnering and financials	11-16	AQ
Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)	23/08/23	AQ
Asarina Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
ASARINA PHARMA - POSITIVE TOURETTE SYNDROME RESULTS TO BE PRESENTED AT ESSTS, 15TH EUROPEAN CONFERENCE ON TOURETTE SYNDROME AND TIC DISORDERS	24/05/23	AQ
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	22/05/23	AQ
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	08/05/23	AQ
Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	05/05/23	AQ
Asarina Pharma's Positive Phase IIa Tourette Syndrome Results to Be Presented At Ticcon, the Virtual National Conference of the Tourette Association of America	05/05/23	CI
Asarina Pharma AB (publ) releases Annual Report 2022	01/05/23	AQ
Asarina Pharma AB (publ) releases Annual Report 2022	28/04/23	AQ
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)	18/04/23	AQ
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette syndrome	03/04/23	AQ
Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome	01/04/23	AQ
Asarina Pharma AB (publ) releases Year-End Report 2022	27/02/23	AQ
Asarina Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Last Patient Last Visit for landmark Tourette Syndrome study	02/02/23	AQ
Asarina Pharma - Patient recruitment completed in landmark Tourette syndrome study	17/10/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Asarina Pharma AB (publ) Nasdaq Stockholm

Equities

SE0011641794

Summary

Filters